CN104471394B - 用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物 - Google Patents

用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物 Download PDF

Info

Publication number
CN104471394B
CN104471394B CN201380027520.5A CN201380027520A CN104471394B CN 104471394 B CN104471394 B CN 104471394B CN 201380027520 A CN201380027520 A CN 201380027520A CN 104471394 B CN104471394 B CN 104471394B
Authority
CN
China
Prior art keywords
cd11b
lin
cell
level
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380027520.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104471394A (zh
Inventor
M·艾森巴赫-施瓦兹
E·尤乐思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New Locust Ltd
Yeda Research and Development Co Ltd
Original Assignee
New Locust Ltd
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Locust Ltd, Yeda Research and Development Co Ltd filed Critical New Locust Ltd
Publication of CN104471394A publication Critical patent/CN104471394A/zh
Application granted granted Critical
Publication of CN104471394B publication Critical patent/CN104471394B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380027520.5A 2012-03-26 2013-03-21 用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物 Active CN104471394B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615465P 2012-03-26 2012-03-26
US61/615,465 2012-03-26
PCT/IL2013/050277 WO2013144957A1 (en) 2012-03-26 2013-03-21 Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression

Publications (2)

Publication Number Publication Date
CN104471394A CN104471394A (zh) 2015-03-25
CN104471394B true CN104471394B (zh) 2017-04-05

Family

ID=49258360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380027520.5A Active CN104471394B (zh) 2012-03-26 2013-03-21 用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物

Country Status (10)

Country Link
US (1) US20150057176A1 (enExample)
EP (1) EP2831584B1 (enExample)
JP (1) JP6276252B2 (enExample)
KR (1) KR20140145173A (enExample)
CN (1) CN104471394B (enExample)
AU (1) AU2013239070A1 (enExample)
CA (1) CA2907909A1 (enExample)
ES (1) ES2819174T3 (enExample)
IL (1) IL234779A (enExample)
WO (1) WO2013144957A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6312302B2 (ja) * 2014-01-06 2018-04-18 公益財団法人ヒューマンサイエンス振興財団 脳梗塞の診断マーカー
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US20220170908A1 (en) * 2019-03-26 2022-06-02 Anton Wyss-Coray Compositions and methods for characterizing and treating alzheimers disease
WO2021072650A1 (zh) * 2019-10-15 2021-04-22 湖南乾康科技有限公司 中间型单核细胞在制备诊断和预测ad药物中的应用
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN112562867A (zh) * 2021-02-22 2021-03-26 天津迈德新医药科技有限公司 一种预测极早期hiv感染风险的装置、存储介质和电子装置
CN118541152A (zh) * 2021-11-02 2024-08-23 特朗奎斯治疗股份有限公司 具有循环髓样细胞炎性表型的受试者的选择和治疗
KR102745500B1 (ko) * 2022-09-02 2024-12-23 한양대학교 에리카산학협력단 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법
CN116270741B (zh) * 2023-02-28 2025-10-24 东莞市东南部中心医院 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1427726A (zh) * 2000-01-20 2003-07-02 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
CN1617736A (zh) * 2001-12-06 2005-05-18 耶达研究及发展有限公司 治疗运动神经元疾病的疫苗和方法
CN102186504A (zh) * 2008-09-18 2011-09-14 西塞医疗中心 用于检测阿尔兹海默病的光学方法
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137108A1 (en) * 2000-11-08 2002-09-26 Michael Mullan CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1427726A (zh) * 2000-01-20 2003-07-02 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
CN1617736A (zh) * 2001-12-06 2005-05-18 耶达研究及发展有限公司 治疗运动神经元疾病的疫苗和方法
CN102186504A (zh) * 2008-09-18 2011-09-14 西塞医疗中心 用于检测阿尔兹海默病的光学方法
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression

Also Published As

Publication number Publication date
EP2831584A1 (en) 2015-02-04
JP2015511721A (ja) 2015-04-20
AU2013239070A1 (en) 2014-11-13
CA2907909A1 (en) 2013-10-03
KR20140145173A (ko) 2014-12-22
EP2831584B1 (en) 2020-06-17
WO2013144957A1 (en) 2013-10-03
US20150057176A1 (en) 2015-02-26
ES2819174T3 (es) 2021-04-15
JP6276252B2 (ja) 2018-02-07
IL234779A (en) 2017-12-31
CN104471394A (zh) 2015-03-25
EP2831584A4 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
CN104471394B (zh) 用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物
Milo et al. Revised diagnostic criteria of multiple sclerosis
Cui et al. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
Leonpacher et al. Distinguishing bipolar from unipolar depression: the importance of clinical symptoms and illness features
Fahmi et al. Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis
Chen et al. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood
US20150209404A1 (en) Cellular blood markers for early diagnosis of als and for als progression
Qi et al. Overexpression of programmed cell death-1 and human leucocyte antigen-DR on circulatory regulatory T cells in out-of-hospital cardiac arrest patients in the early period after return of spontaneous circulation
Green et al. Blood biomarkers discriminate cerebral amyloid status and cognitive diagnosis when collected with ACD-A anticoagulant
Frisullo et al. The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis
JP6115979B2 (ja) Ｓｍｎタンパク質の発現を検出する方法
US20200158738A1 (en) Diagnostic markers of cognitive impairments, kits and uses thereof
CN108196051B (zh) 包含cd14检测试剂的梅毒检测试剂盒及该试剂在梅毒检测中的应用
CA2941460C (en) Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease
CN117460956A (zh) 外周血巨噬细胞在制备用于阿尔兹海默病诊断、预后及治疗的试剂和/或药物中的应用
WO2023000688A1 (zh) 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用
US12072335B2 (en) Method of evaluating progression of an infectious disease and/or inflammatory disease
KR102199141B1 (ko) 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
Rodríguez-Martín et al. Diagnosis of Diffuse Interstitial Lung Diseases: BAL Study-Its Utility for the Diagnosis
CN117230144A (zh) 抑郁症诊断、药物治疗效果预测的生物标志物
Lloyd-Smith et al. Early clinical features differentiate cerebellar variant MSA and sporadic ataxia
Lu et al. Predicting the conversion to Alzheimer’s disease in individuals with late onset depression using CARE index
Aljumah et al. Genetic variation among multiple sclerosis in Saudi patients
Zeng et al. The applications and clinical significance of IMA, H-FABP joint CK-MB in acute myocardial infarction
Younkin et al. Trisha M. Stan1, Philipp A. Jaeger1, Markus Britschgi1, Daniela Berdnik1, Ruo-Pan Huang2, Bradley F. Boeve3, Adam L. Boxer4, Nicole Finch5, Gabriela K. Fragiadakis6, Robert Bruggner6, Neill R. Graff-Radford5, Ruochun Huang4, Hudson Johns1, Anna Karydas4, David S. Knopman3, Michael Leipold6, 7, Holden Maecker6, 7, Zachary Miller4, Ronald C. Petersen5, Rosa Rademakers5, Chung-Huan Sun1, Steve

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant